Developer docs
API playgroundTry for free, no card

Search company profiles

AZTherapies

Full company profile

uuid000264k

Namestring
AZTherapies
Websiteurl
aztherapies.com
Company typeenum
Private
Founded yearint
2011
Short descriptiontext

AZTherapies is a privately held, Boston-based clinical-stage biotech founded in 2011 that develops proprietary therapeutics for neuroinflammation-related diseases, led by Scientific Founder/CEO David Elmaleh with Rudolph Tanzi chairing its Scientific Advisory Board.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical stage biotech, neuroinflammation therapeutics, Alzheimer's disease drugs, CNS drug development, biopharmaceutical research
Industry1 code
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • All Other Professional, Scientific, and Technical Services54199
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Social media profiles1 record
Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeBiopharmaceuticals
Biopharmaceuticals
Core offering1 text field

AZTherapies is a clinical-stage biotechnology company developing breakthrough therapeutic treatments for neuroinflammation-related diseases. The company advances a pipeline of drug candidates targeting central nervous system (CNS) conditions, with research and clinical operations focused on translating neuroinflammation science into disease-modifying therapies.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeBroad incumbent
Description

Co-developer of Leqembi (lecanemab) with Biogen for early Alzheimer's. Direct competitor establishing the amyloid-targeting paradigm that AZTherapies' neuroinflammation approach must differentiate against.

TypeBroad incumbent
Description

Large-cap neuroscience company with approved Alzheimer's antibodies (Aduhelm, Leqembi). Direct competitor in the AD treatment space, with substantially greater resources and commercial reach.

3Cassava Sciences
TypeDirect peer
Description

Clinical-stage biotech developing simufilam for Alzheimer's disease. Comparably sized, late-clinical-stage peer in the AD space pursuing a non-amyloid mechanism of action.

TypeEmerging player
Description

Was developing atuzaginstat for Alzheimer's targeting a P. gingivalis neuroinflammation mechanism before corporate restructuring. Historical direct peer in neuroinflammation-modulated AD therapeutics.

TypeDirect peer
Description

Clinical-stage biotech developing ANAVEX compounds (e.g., blarcamesine) for Alzheimer's, Rett syndrome and other neurodegenerative indications. Comparably sized peer in CNS drug development.

TypeDirect peer
Description

Clinical-stage biotech with a pipeline of protein immunotherapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable in stage, modality and disease focus.

TypeDirect peer
Description

Clinical-stage biotech with a neurodegeneration and neuroinflammation pipeline (e.g., DNL151, TREM2 programs). Compares on disease focus and stage, with broader CNS pipeline diversification.

TypeDirect peer
Description

Clinical-stage biotech developing XPro1595, a TNF inhibitor targeting neuroinflammation in Alzheimer's and other CNS diseases. Most direct mechanistic peer to AZTherapies' neuroinflammation thesis.

TypeDirect peer
Description

Clinical-stage biotech developing immuno-neurology therapies (AL001, AL002) for neurodegenerative diseases including frontotemporal dementia and Alzheimer's. Closely comparable in modality and disease focus.

TypeBroad incumbent
Description

Major pharma with Kisunla (donanemab), an FDA-approved anti-amyloid antibody for Alzheimer's. Competes in the same disease via a different mechanism, setting the standard of care.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AZTherapies

AZTherapies is a privately held, Boston-based clinical-stage biotech founded in 2011 that develops proprietary therapeutics for neuroinflammation-related diseases, led by Scientific Founder/CEO David Elmaleh with Rudolph Tanzi chairing its Scientific Advisory Board.

AZTherapies firmographics

Firmographics
Name
AZTherapies
Website
https://aztherapies.com
Company type
Private
Founded year
2011
Headcount range
1–10 employees
Short description
AZTherapies is a privately held, Boston-based clinical-stage biotech founded in 2011 that develops proprietary therapeutics for neuroinflammation-related diseases, led by Scientific Founder/CEO David Elmaleh with Rudolph Tanzi chairing its Scientific Advisory Board.
Ownership category
akta.pro rank

AZTherapies industry classification

Industry
NAICS
All Other Professional, Scientific, and Technical Services (54199)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Clinical stage biotech
  • Neuroinflammation therapeutics
  • Alzheimer's disease drugs
  • CNS drug development
  • Biopharmaceutical research

Where AZTherapies is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

AZTherapies business model

Business model
GTM type
B2B
Offering type
Biopharmaceuticals
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

AZTherapies product offering

Product offering

Core offering

AZTherapies is a clinical-stage biotechnology company developing breakthrough therapeutic treatments for neuroinflammation-related diseases. The company advances a pipeline of drug candidates targeting central nervous system (CNS) conditions, with research and clinical operations focused on translating neuroinflammation science into disease-modifying therapies.

Differentiator

Problem solved

Functional benefit

Companies that use AZTherapies

Customer profile

Ideal customer profiles1 record

AZTherapies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AZTherapies competitors and assessment

Company assessment

Broad incumbents

  • Eisai: Co-developer of Leqembi (lecanemab) with Biogen for early Alzheimer's. Direct competitor establishing the amyloid-targeting paradigm that AZTherapies' neuroinflammation approach must differentiate against.
  • Biogen: Large-cap neuroscience company with approved Alzheimer's antibodies (Aduhelm, Leqembi). Direct competitor in the AD treatment space, with substantially greater resources and commercial reach.
  • Eli Lilly: Major pharma with Kisunla (donanemab), an FDA-approved anti-amyloid antibody for Alzheimer's. Competes in the same disease via a different mechanism, setting the standard of care.

Direct peers

  • Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease. Comparably sized, late-clinical-stage peer in the AD space pursuing a non-amyloid mechanism of action.
  • Anavex Life Sciences: Clinical-stage biotech developing ANAVEX compounds (e.g., blarcamesine) for Alzheimer's, Rett syndrome and other neurodegenerative indications. Comparably sized peer in CNS drug development.
  • Prothena: Clinical-stage biotech with a pipeline of protein immunotherapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable in stage, modality and disease focus.
  • Denali Therapeutics: Clinical-stage biotech with a neurodegeneration and neuroinflammation pipeline (e.g., DNL151, TREM2 programs). Compares on disease focus and stage, with broader CNS pipeline diversification.
  • INmune Bio: Clinical-stage biotech developing XPro1595, a TNF inhibitor targeting neuroinflammation in Alzheimer's and other CNS diseases. Most direct mechanistic peer to AZTherapies' neuroinflammation thesis.
  • Alector: Clinical-stage biotech developing immuno-neurology therapies (AL001, AL002) for neurodegenerative diseases including frontotemporal dementia and Alzheimer's. Closely comparable in modality and disease focus.

Emerging players

  • Cortexyme (now Spyre Therapeutics): Was developing atuzaginstat for Alzheimer's targeting a P. gingivalis neuroinflammation mechanism before corporate restructuring. Historical direct peer in neuroinflammation-modulated AD therapeutics.

Market position

Customer concentration

AZTherapies social profiles

Digital presence

AZTherapies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AZTherapies leadership team

Management profile

Number of profiles

Profiles14 records

AZTherapies funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AZTherapies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AZTherapies

What does AZTherapies do?

AZTherapies is a clinical-stage biotechnology company developing breakthrough therapeutic treatments for neuroinflammation-related diseases. The company advances a pipeline of drug candidates targeting central nervous system (CNS) conditions, with research and clinical operations focused on translating neuroinflammation science into disease-modifying therapies.

When was AZTherapies founded?

AZTherapies was founded in 2011. It employs 1 to 10 people.

Where is AZTherapies based?

AZTherapies is headquartered in Boston, United States, in the North America region.

Who are AZTherapies's main competitors?

Broad incumbents on record are Eisai, Biogen and Eli Lilly. Direct peers are Cassava Sciences, Anavex Life Sciences, Prothena, Denali Therapeutics, INmune Bio and Alector. Cortexyme (now Spyre Therapeutics) is listed as an emerging player.

Does AZTherapies have an API?

No public API is recorded for AZTherapies.

What industry is AZTherapies in?

Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 54199 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
IntelligentHQPhilip Ashton-Rickardt on Why Starting Over Rarely Means Starting From ScratchPhilip Ashton-Rickardt, a biotech entrepreneur and scientist, argues that career changes rarely mean starting from scratch because skills and judgment carry over. He moved from academia to founding Smith Therapeutics and later roles at AZTherapies, Sigilon, and Flagship Pioneering, emphasizing curiosity and flexibility. He now co-founded Halyard Therapeutics and serves as CMO at BE Therapeutics.CEOWORLD magazinePhilip Ashton-Rickardt: From Lab to Biotech LeadershipPhilip Ashton-Rickardt, a UK-born scientist, left academia to found Smith Therapeutics in 2017, which he sold to AZTherapies. He later led Sigilon Therapeutics, acquired by Eli Lilly in 2023, and now serves as MD/CSO at BE Therapeutics and co-founder of Halyard Therapeutics.FierceBiotechEx-Ipsen boss de Garidel takes the helm at AZTherapiesMarc de Garidel, former Ipsen CEO, has been named CEO of AZTherapies, a neurodegenerative disease biotech. The company's lead drug ALZT-OP1 is in Phase 3 for early Alzheimer's, with the trial expected to conclude by year-end. De Garidel expects to raise $200 million for U.S. commercialization.GlobeNewswireAZTherapies Announces the Appointment of Drs. Robert Malenka, Adam Boxer, Vijay Kuchroo and Megan Levings, to Scientific Advisory BoardAZTherapies appointed Robert Malenka, Adam Boxer, Vijay Kuchroo, and Megan Levings to its Scientific Advisory Board. The appointments follow the company's acquisition of Smith Therapeutics in October 2019. The board members will support AZTherapies' neuroinflammation-focused pipeline, including its Phase 3 Alzheimer's trial.GlobeNewswireAZTherapies Strengthens Board of Directors & Business Advisory Board with New AppointmentsAZTherapies appointed Noah Gottdiener and Thierry Porté to its Board of Directors and Joseph Kelley to its Business Advisory Board. The company's lead Alzheimer's candidate ALZT-OP1 is in Phase 3, with trial completion expected in late 2020 and data unblinding in Q1 2021.PR NewswireEine neue Publikation bestätigt den innovativen Arzneimittelkombinationsansatz von AZTherapies zur Behandlung der Neuroinflammationsreaktion mittels Neuroimmunologie und Amyloid-Beta-Anhäufung, die miAZTherapies announced that a study published in Scientific Reports supports the scientific rationale for its lead drug candidate ALZT-OP1, a combination of Cromolyn and Ibuprofen, in treating early-stage Alzheimer's disease. The research demonstrated that this combination reduces amyloid-beta levels by promoting microglial phagocytosis in preclinical models. This validation underpins the ongoing Phase III COGNITE clinical trial aimed at slowing cognitive decline in Alzheimer's patients.PR NewswireUne nouvelle publication confirme l'approche d'AZTherapies consistant à associer des médicaments innovants pour traiter la réponse neuroinflammatoire via la neuroimmunologie et l'accumulation de bêta-AZTherapies announced that a January 2018 study published in Scientific Reports supports its strategy of combining cromolyn acid and ibuprofen to treat Alzheimer's disease by reducing amyloid beta levels. The research, conducted at Harvard Medical School and Massachusetts General Hospital, validates the preclinical efficacy of the ALZT-OP1 candidate currently undergoing Phase 3 trials. This development reinforces the scientific justification for AZTherapies' neuroimmunology approach in slowing cognitive decline.PR NewswireEen nieuwe publicatie bevestigt de innovatieve aanpak van de medicijncombinatie van AZTherapies voor de neuroinflammatoire respons via neuro-immunologie en amyloïde beta-accumulatie die wordt geassociAZTherapies announced that a scientific paper published in Nature's Scientific Reports by Dr. Rudolph Tanzi's lab at Harvard Medical School and Massachusetts General Hospital supports the company's drug combination approach (ALZT-OP1) for early-stage Alzheimer's disease treatment. The research demonstrates that cromolyn and ibuprofen, the two drugs in the COGNITE Phase 3 trial, reduce amyloid beta protein levels by promoting microglial phagocytosis in a mouse model. The ongoing COGNITE trial has screened 900 patients with over 300 randomized out of the planned 600 participants.PR NewswireA new publication confirms AZTherapies's innovative drug combination approach to address the neuroinflammation response via neuro-immunology and amyloid beta accumulation associated with neurodegeneraAZTherapies confirmed its drug combination approach for Alzheimer's disease by citing a January 2018 study published in Scientific Reports that supports the efficacy of cromolyn and ibuprofen. The research, conducted at Harvard Medical School and Massachusetts General Hospital, demonstrated that these drugs reduce amyloid beta levels and promote microglial phagocytosis in mouse models. This validation underpins AZTherapies' ongoing Phase 3 COGNITE trial for its lead candidate ALZT-OP1.